2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 839

Use of Bisphosphonate and Risk of Incident Atrial Fibrillation in a Population-Based Study
Abstract Number: 840

Mortality Post Hip Fracture in Rheumatoid Arthritis Compared to General Population Controls, a Population-Based Study
Abstract Number: 841

Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: 52-Week Follow-up of a Non-Blinded, Randomized Controlled Trial
Abstract Number: 842

Risk of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologic Vs. Non-Biologic Dmards
Abstract Number: 843

The Role of Personality in Patients with Fibromyalgia
Abstract Number: 844

Social Support, Stress and Health Outcomes in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Abstract Number: 845

Effectiveness of Brief Group Psychoanalytic Psychotherapy in Patients with Systemic Lupus Erythematosus and Follow-up
Abstract Number: 846

Social Support in Couples-Focused Physical Activity Interventions for People with Hip or Knee Osteoarthritis: What Kinds of Partner Support Are Associated with Increases in Physical Activity and Reductions in Sedentary Behavior?
Abstract Number: 847

The Mediational Role of Helplessness in Psychological Outcomes in Systemic Lupus Erythematosus
Abstract Number: 848

“Suddenly You Are a Person at Risk of Developing Rheumatoid Arthritis!” Different Perspectives of Individuals on Predictive Testing – Results of an International Qualitative Interview Study
Abstract Number: 849

Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis
Abstract Number: 850

Immune Checkpoint Inhibitors and Inflammatory Myopathies: Data from the US Food and Drug Administration Adverse Event Reporting System
Abstract Number: 851

Autoantibodies Predict Long Term Survival in Myositis Associated Interstitial Lung Disease
Abstract Number: 852

RNAseq Detection of Gene Dysregulation in PBMCs from Juvenile Dermatomyositis, Positive for p155/140 Myositis Specific Antibody
Abstract Number: 853

Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].